• Algernon Pharmaceuticals (AGN) has established the optimum peak stimulation period for neuron outgrowth by AP-188 (DMT) in its pre-clinical in vitro study
  • This current data set is from the second part of Algernon’s in vitro experiment designed to focus on duration of infusion needed to achieve maximal cortical neuron outgrowth
  • The final data set from the study is expected to be completed by the end of November 2021
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.08 per share

Algernon Pharmaceuticals (AGN) has established the optimum peak stimulation period for neuron outgrowth by AP-188 (DMT) in its pre-clinical in vitro study.

The study, conducted by Charles River Laboratories, also confirms that the increased growth was achieved with a sub-hallucinogenic dose.

This current data set is from the second part of Algernon’s in vitro experiment designed to focus on the duration of infusion needed to achieve maximal cortical neuron outgrowth.

Chris Moreau, CEO of Algernon Pharmaceuticals spoke with Caroline Egan to discuss the news.

The data showed that an increase in growth of over 40 per cent was observed in the group treated for 6 hours with 30 nM DMT when compared to control. The results from the 6-hour period were superior to other treatment time periods and doses.

The final data set from the study will focus on investigating the mechanisms related to DMT which may be causing the growth of the neurons and is expected to be completed by the end of November 2021.

Algernon has established a clinical research program for the treatment of stroke focused on DMT, a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin).

Algernon has also filed new provisional patents for new forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and Constraint-Induced Movement Therapy (“CIMT”).

Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.08 per share.

More From The Market Online

Mullen Group: Navigates market challenges towards success

Mullen Group Ltd. (TSX:MTL), a prominent player in Canada’s logistics landscape, has recently released its Q1 2024 results.
BriaCell Therapeutics Corp

BriaCell to report positive cancer research at medical convention

BriaCell Therapeutics (TSX:BCT) will present positive clinical data of Bria-IMT at the 2024 American Society of Clinical Oncology in Chicago.

@ the Bell: TSX gains on latest economic report

Mining stocks led gainers on the TSX, followed by the financial sector, while the telecom market was the biggest decliner.

The Market Online’s Weekly Cannabis Report – May 24, 2024

A global cannabis stock intends to raise up to US$250 million through an at-the-market equity program to fund its U.S. expansion plan.